{"filing":{"accession_number":"0001055726-26-000024","cik":"0001055726","ticker":"INO","company_name":"INOVIO PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"ino-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-20260812.htm"},"events":[{"id":27181,"run_id":24754,"accession_number":"0001055726-26-000024","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Inovio's financial results for Q2 2026 (quarter ended June 30, 2026), including consolidated balance sheets, statements of operations, and detailed financial metrics (R\u0026D expenses, G\u0026A expenses, net loss per share). The filing explicitly states \"INOVIO Reports Second Quarter 2026 Financial Results\" and includes quantitative results such as net loss of $6.0 million ($0.07 per share) versus $23.5 million ($0.61 per share) in the prior year period, along with cash position and operational guidance through Q1 2027.","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28603,"accession_number":"0001055726-26-000024","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Inovio's financial results for Q2 2026 (quarter ended June 30, 2026), including consolidated balance sheets, statements of operations, and detailed financial metrics (R\u0026D expenses, G\u0026A expenses, net loss per share). The filing explicitly states \"INOVIO Reports Second Quarter 2026 Financial Results\" and includes quantitative results such as net loss of $6.0 million ($0.07 per share) versus $23.5 million ($0.61 per share) in the prior year period, along with cash position and operational guidance through Q1 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:12:40.761314+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28603,"accession_number":"0001055726-26-000024","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Inovio's financial results for Q2 2026 (quarter ended June 30, 2026), including consolidated balance sheets, statements of operations, and detailed financial metrics (R\u0026D expenses, G\u0026A expenses, net loss per share). The filing explicitly states \"INOVIO Reports Second Quarter 2026 Financial Results\" and includes quantitative results such as net loss of $6.0 million ($0.07 per share) versus $23.5 million ($0.61 per share) in the prior year period, along with cash position and operational guidance through Q1 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:12:40.761314+00:00","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-08-12"}]}